Topic resource collection
Approved comparison material connected to this topic.
479 resourcesRead both sides
| Peptide | Mechanism | Half-Life | Typical Dosing Protocol | Secondary Hormonal Effects | Desensitization Risk | Research Application ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH analog | 6–8 days | 1–2 mg once weekly | Minimal—GH…
Thymalin Thymic restoration, T-cell maturation Immune senescence, SASP reduction Phase II: 34% increase CD4+ T-cells, 22% reduction SASP markers (12 weeks, Immunity & Ageing 2021) 10mg subcutaneous, twice weekly Most overlooked d…
The table below compares the most clinically validated peptides for appetite and craving suppression based on mechanism, dosing, half-life, and documented efficacy. Semaglutide GLP-1 receptor agonist. Delays gastric emptying, sup…
Timing determines which peptides matter. Acute-phase interventions (0–14 days post-injury) target excitotoxicity and blood-brain barrier stabilisation. Chronic-phase protocols (2+ months post-injury) focus on neuroplasticity, den…
| Peptide | Mechanism | Half-Life | Typical Research Dose | IGF-1 Elevation (%) | Synergy Potential | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH receptor agonist | 6–8 days | 30–60 mcg/kg weekly | 60–80% |…
Melanotan II MC1R agonist, triggers eumelanin via cAMP-MITF pathway 0.5–1.0mg SC daily (loading), 0.5mg weekly (maintenance) 5–7 days visible, peak at 4–6 weeks SPF 3–4 per skin type increase Most researched, highest receptor aff…
This table compares the three peptides with the most compelling preclinical evidence for accelerating ulcer repair. BPC-157 VEGF receptor activation → angiogenesis + fibroblast proliferation Oral or subcutaneous 88% ulcer reducti…
Before implementing any peptide protocol, understanding mechanism differences determines which compounds address specific injury profiles. The table below compares primary mechanisms, documented applications, typical research dos…
GHK-Cu (Copper Peptide) TGF- downregulation, VEGF upregulation, collagen synthesis in dermal papilla 340 Da Topical (penetrates intact skin) 18% hair count increase at 12 weeks (Journal of Drugs in Dermatology, 2015) Strongest cl…
Cerebrolysin Neurotrophic factor delivery (BDNF, NGF, CNTF) Restores prefrontal BDNF deficits; enhances synaptic plasticity for habit remodeling 10–30mL IV infusion, 10–20 sessions over 4–8 weeks 4–6 hours; IV only Most evidence …
| Peptide | Primary Mechanism | Panic-Relevant Action | Human Trial Evidence | Typical Research Dose | Administration Route | Professional Assessment ||—|—|—|—|—|—|| BPC-157 | Gastric protection, unclear CNS pathway | Normalizes …
Before selecting peptides for rotator cuff research, compare their mechanisms, dosing complexity, and storage requirements. This table summarises the three categories most relevant to tendon healing models. BPC-157 Upregulates VE…
Before selecting peptides for IBD research protocols, understanding their distinct mechanisms, administration routes, and evidence quality clarifies which compound fits specific research goals. BPC-157 VEGF upregulation, FAK phos…
CJC-1295/Ipamorelin GH secretagogue. Increases lipolysis via HSL activation Moderate (visceral adipocytes express 40% more GH receptors than subcutaneous) Weekly (CJC) + daily (Ipamorelin) 12.3% visceral fat reduction at 24 weeks…
BPC-157 VEGF upregulation → angiogenesis at injury sites; promotes fibroblast migration and collagen synthesis Subcutaneous injection (daily) 200–500mcg/day for 4–8 weeks Symptomatic pain reduction: 7–14 days; structural healing …
This table compares the three peptides generating the most HSV-focused research attention based on mechanism, research evidence strength, and practical research application considerations. Thymosin Alpha-1 CD4+ T-cell upregulatio…
Follistatin Binds activin to enhance FSH receptor sensitivity in granulosa cells Diminished ovarian reserve, poor responder protocols 1–3 mg/kg subcutaneously during early follicular phase Subcutaneous injection Promising for DOR…
Reduced L-Glutathione (GSH) Direct thiol-mediated binding; GST-catalysed conjugation; biliary and renal excretion Mercury, lead, cadmium, arsenic (divalent metals) 500–1000mg twice daily (oral); 600–1200mg IV (clinical chelation …
Thymalin Thymic T-cell restoration via thymulin receptor activation Moderate (Phase 2–3 trials in immune restoration; observational data in herpesvirus contexts) 5–10mg subcutaneous every 48–72 hours × 14–28 days 30–40% reduction…
Thymalin Thymic epithelial growth factor upregulation → T-cell differentiation Bone marrow, thymus, lymphoid tissue 24–72 hours (optimal); effective up to 7 days Strong. Multiple controlled animal studies; Russian clinical data i…